{"url_path":"/sec/eltp/8-k/2026-08-11/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K/A","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1053369/0001493152-26-036936-index.html","accession_number":"0001493152-26-036936","cik":"0001053369","ticker":"ELTP","issuer_name":"ELITE PHARMACEUTICALS INC /NV/","edgar_url":"https://www.sec.gov/Archives/edgar/data/1053369/0001493152-26-036936-index.html","primary_entity_key":"0001053369","primary_entity_name":"ELITE PHARMACEUTICALS INC /NV/"},"word_count":290,"has_tables":true,"body_markdown":"**Item\n7.01. Regulation FD Disclosure.**\n\n \n\nOn\nAugust 10, 2026, Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) issued a press release announcing that\nthe Company will host a conference call to discuss its financial results for the first quarter of fiscal year 2027 ended June 30, 2026,\non Thursday, November 14, 2026, at 11:30 AM EDT. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by\nreference herein.\n\n** **\n\n**Conference\nCall Information**\n\n** **\n\nDate:\n\nAugust\n14, 2026\n\nTime:\n\n11:30\nAM EDT\n\nDial-in\nnumbers:\n1-800-346-7359\n(domestic)\n\n \n1-973-528-0008\n(international)\n\nConference\nnumber:\n98840\n\nQuestions:\ndianne@elitepharma.com\n\n \nGeneral\nquestions by 5:00 PM EDT on Wednesday, August 12, 2026\n\n \nFinancial\nquestions by 7:00 PM EDT on Friday, August 13, 2026\n\n** **\n\nThe\ninformation disclosed in Item 2.02 above is incorporated into this Item 7.01. The information included in this Current Report on Form\n8-K (including the exhibit hereto) is being furnished under Item 2.02, “Results of Operations and Financial Condition,” Item\n7.01, “Regulation FD Disclosure” and Item 9.01 “Financial Statements and Exhibits” of Form 8-K. As such, the\ninformation (including the exhibit) herein shall not be deemed to be “filed” for the purposes of Section 18 of the Securities\nExchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall\nit be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general\nincorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing. This Current Report\n(including the exhibit hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely\nto satisfy the requirements of Regulation FD."}